262 related articles for article (PubMed ID: 29101636)
1. LyP-1 Conjugated Nanoparticles for Magnetic Resonance Imaging of Triple Negative Breast Cancer.
Abulrob A; Corluka S; Blasiak B; Gino Fallone B; Ponjevic D; Matyas J; Tomanek B
Mol Imaging Biol; 2018 Jun; 20(3):428-435. PubMed ID: 29101636
[TBL] [Abstract][Full Text] [Related]
2. Optical Imaging of Triple-Negative Breast Cancer Cells in Xenograft Athymic Mice Using an ICAM-1-Targeting Small-Molecule Probe.
Zhang Y; Wang M; Liu W; Peng X
Mol Imaging Biol; 2019 Oct; 21(5):835-841. PubMed ID: 30623283
[TBL] [Abstract][Full Text] [Related]
3.
Song N; Zhao L; Zhu M; Zhao J
Contrast Media Mol Imaging; 2019; 2019():9502712. PubMed ID: 31598115
[TBL] [Abstract][Full Text] [Related]
4. Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-1 in Human Breast Cancer.
Timur SS; Bhattarai P; Gürsoy RN; Vural İ; Khaw BA
Pharm Res; 2017 Feb; 34(2):352-364. PubMed ID: 27896591
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
6. Fe
Yin Q; Gao X; Zhang H; Zhang Z; Yu X; He J; Shi G; Hao L
Biomed Mater; 2024 Apr; 19(3):. PubMed ID: 38626777
[TBL] [Abstract][Full Text] [Related]
7. Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancer.
Zhang H; Li J; Hu Y; Shen M; Shi X; Zhang G
J Ovarian Res; 2016 Mar; 9():19. PubMed ID: 27025582
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeling LyP-1 peptide and preliminary biodistribution evaluation in mice bearing MDA-MB-435 xenografts.
Yu MM; Wang RF; Chen YH; Zhou HZ; Deng XH
Chin Med J (Engl); 2013 Feb; 126(3):471-5. PubMed ID: 23422109
[TBL] [Abstract][Full Text] [Related]
9. ZD2-Engineered Gold Nanostar@Metal-Organic Framework Nanoprobes for T
Zhang L; Liu C; Gao Y; Li Z; Xing J; Ren W; Zhang L; Li A; Lu G; Wu A; Zeng L
Adv Healthc Mater; 2018 Dec; 7(24):e1801144. PubMed ID: 30370656
[TBL] [Abstract][Full Text] [Related]
10. Targeted MR Imaging Adopting T1-Weighted Ultra-Small Iron Oxide Nanoparticles for Early Hepatocellular Carcinoma: An
Xu YH; Yang J; Meng J; Wang H
Chin Med Sci J; 2020 Jun; 35(2):142-150. PubMed ID: 32684234
[TBL] [Abstract][Full Text] [Related]
11. LyP-1-conjugated Fe
Teo P; Wang X; Zhang J; Zhang H; Yang X; Huang Y; Tang J
J Biomater Sci Polym Ed; 2018 Feb; 29(2):181-194. PubMed ID: 29165044
[TBL] [Abstract][Full Text] [Related]
12. Fibronectin-Targeting and Cathepsin B-Activatable Theranostic Nanoprobe for MR/Fluorescence Imaging and Enhanced Photodynamic Therapy for Triple Negative Breast Cancer.
Wang Y; Jiang L; Zhang Y; Lu Y; Li J; Wang H; Yao D; Wang D
ACS Appl Mater Interfaces; 2020 Jul; 12(30):33564-33574. PubMed ID: 32633941
[TBL] [Abstract][Full Text] [Related]
13. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts.
Ke S; Wen X; Gurfinkel M; Charnsangavej C; Wallace S; Sevick-Muraca EM; Li C
Cancer Res; 2003 Nov; 63(22):7870-5. PubMed ID: 14633715
[TBL] [Abstract][Full Text] [Related]
14. In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models.
Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
Anticancer Res; 2016 Dec; 36(12):6273-6277. PubMed ID: 27919946
[TBL] [Abstract][Full Text] [Related]
15. Application of luteinizing hormone-releasing hormone-ferrosoferric oxide nanoparticles in targeted imaging of breast tumors.
Nian D; Shi P; Sun J; Ren L; Hao X; Han J
J Int Med Res; 2019 Apr; 47(4):1749-1757. PubMed ID: 30880516
[TBL] [Abstract][Full Text] [Related]
16. A Comparative Study of Receptor-Targeted Magnetosome and HSA-Coated Iron Oxide Nanoparticles as MRI Contrast-Enhancing Agent in Animal Cancer Model.
Erdal E; Demirbilek M; Yeh Y; Akbal Ö; Ruff L; Bozkurt D; Cabuk A; Senel Y; Gumuskaya B; Algın O; Colak S; Esener S; Denkbas EB
Appl Biochem Biotechnol; 2018 May; 185(1):91-113. PubMed ID: 29082480
[TBL] [Abstract][Full Text] [Related]
17. Integrin α
Li D; Dong C; Ma X; Zhao X
Cancer Imaging; 2021 Jun; 21(1):44. PubMed ID: 34187570
[TBL] [Abstract][Full Text] [Related]
18. MRI reveals increased tumorigenesis following high fat feeding in a mouse model of triple-negative breast cancer.
Mustafi D; Fernandez S; Markiewicz E; Fan X; Zamora M; Mueller J; Brady MJ; Conzen SD; Karczmar GS
NMR Biomed; 2017 Oct; 30(10):. PubMed ID: 28661075
[TBL] [Abstract][Full Text] [Related]
19. Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
Wang M; Liu W; Zhang Y; Dang M; Zhang Y; Tao J; Chen K; Peng X; Teng Z
J Colloid Interface Sci; 2019 Mar; 538():630-637. PubMed ID: 30554096
[TBL] [Abstract][Full Text] [Related]
20. In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5.5.
Lin YH; Dayananda K; Chen CY; Liu GC; Luo TY; Hsu HS; Wang YM
Bioorg Med Chem; 2011 Feb; 19(3):1085-96. PubMed ID: 20493715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
